Can asthma inhalers prevent COVID-19 hospitalisations? The STOIC Study - Prof Mona Bafadhel

In this talk from 16 March 2021, Prof Mona Bafadhel discusses her recent research on the use of inhaled corticosteroids (usually used for asthma and COPD) to reduce the chances of severe respiratory illness in COVID-19 patients. Mona Bafadhel is Associate Professor of Respiratory Medicine at the University of Oxford and a Consultant Respiratory Physician. Her research focuses on chronic obstructive pulmonary disease (COPD), a set of conditions that cause the airways to become inflamed and make it harder for patients to breathe. In this event, Mona talks about: The background to the STOIC study (Steroids in Covid Study) Early clinical observations that respiratory disease was an infrequent finding in people hospitalised with COVID-19 Early laboratory findings that viral replication seemed to be reduced by inhaled corticosteroids What we already know about asthma, COPD and viruses The STOIC Study design - who was eligible to volunteer What happened during the study The study outcomes - primary and secondary endpoints Data on the study volunteers and their symptoms Results of the study - primary and secondary endpoints Strengths and limitations of the study Q&A More information: https://clinicaltrials.gov/ct2/show/N... https://www.ndm.ox.ac.uk/team/mona-ba...